Where does Hoffmann-La Roche Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Hoffmann-La Roche Inc. ranks #425 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Hoffmann-La Roche Inc. hold?

Hoffmann-La Roche Inc. holds 1,065 US utility patents granted between 2015 and 2025, spanning 64 technology areas.

What is Hoffmann-La Roche Inc.'s Innovation Score?

Hoffmann-La Roche Inc. has an Innovation Score of 65.3 out of 100 (top 1% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Hoffmann-La Roche Inc.'s patent grant rate increasing or decreasing?

Hoffmann-La Roche Inc.'s recent grant velocity is -4% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Hoffmann-La Roche Inc.'s patents?

Hoffmann-La Roche Inc.'s patents average 16.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Hoffmann-La Roche Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Hoffmann-La Roche Inc.

Q: What technology areas does Hoffmann-La Roche Inc. focus on?

Hoffmann-La Roche Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 722 patents. Grants appear in 64 CPC subclasses total.

USPTO PatentsView assignee record - 1,065 granted patents across 64 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Hoffmann-la ranks #425 of 49,997 tracked US assignees by granted-patent volume, with 1,065 patents across 64 technology areas.

#425
of 49,997 US assignees by volume: Top 1%
by Innovation Score (65.3/100): 16.2
avg claims per patent: -4%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R425 · US Corporation #425 · 1,065 grants

GRANTS-LARGE · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-LARGE 1.1K grants
TOP-DECILE #425/49,997
PHOTO-FINISH Lawrence Livermore…
CPC-WIDE A61P · 64 areas
INNOV-STRONG 65.3/100
CLAIMS-RICH 16.2 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT -4% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Lawrence Livermore National Security, LLC (±1 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
United States… · near

65
Hoffmann-La Roche · this assignee

65
B/E Aerospace · near

65
Booz Allen Hamilton · near

65
Divergent · near

65
3D Lighting… · lowest

7

What this shows Hoffmann-la's Innovation Score is 65.3/100 (top 1% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

How Hoffmann-la's grant cadence moved

Between 2020–2024, Hoffmann-La Roche Inc. received 487 grants versus 506 in 2015–2019 (-4% equal-window velocity, above median growth). Across complete PatentsView years, output peaked in 2016 at 122 grants and bottomed in 2015 at 74. Lead class A61P accounts for 67.8% of the portfolio across 64 subclasses. Volume neighbours: Screen Holdings Co., Ltd. (#421) and RTX Corporation (#429).

Hoffmann-la's three-year grant acceleration

From 2019–2021 to 2022–2024, Hoffmann-La Roche Inc. moved from 295 to 290 grants (0.98x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,228. See the growth leaderboard.

Screen Holdings

1,077
Hitachi High-tech

1,071
Novatek Microelec…

1,071
Hitachi High-

1,068
Hoffmann-la Roche ◀

1,065
Lawrence Livermor…

1,064
Zoox

1,064
Universal Display

1,058
RTX

1,055

What this shows Hoffmann-La holds 1,065 patents at rank #425, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Hoffmann-La

By rank, the assignees closest to #425 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Hoffmann-La's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Hoffmann-La, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (65 here).

B/E Aerospace, Inc. 65 Booz Allen Hamilton Inc. 65 United States Postal Service 65 Divergent Technologies, Inc. 65

Similar claim depth

Nearest assignees by average claims per patent (16.2 here).

Novelis Inc. 16.2 avg First Data Corporation 16.2 avg Newtonoid Technologies, L.L.C. 16.2 avg Southern Research Institute 16.2 avg

Hoffmann-la's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

65 Top 1% higher than 99% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Hoffmann-La Roche Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	74	6.9%
2016	122	11.5%
2017	108	10.1%
2018	104	9.8%
2019	98	9.2%
2020	105	9.9%
2021	92	8.6%
2022	113	10.6%
2023	83	7.8%
2024	94	8.8%
2025partial year	72	6.8%

Which technologies does Hoffmann-La Roche Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 722

C07D - Heterocyclic Compounds 455

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 418

C07K - Peptides 357

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 122

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 108

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 37

C12Y - Enzymes 36

C07C - Acyclic OR Carbocyclic Compounds 36

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 29

Y02A - Technologies FOR Adaptation TO Climate Change 26

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 25

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 25

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 24

B01D - Separation 20

Top 15 of 64 technology areas

Where it ranks

Overall rank by patents

#425

of 49,997 tracked assignees

Innovation Score

65.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Hoffmann-La Roche Inc.'s patent record in context - here's where to go next.

Hoffmann-La Roche Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 67.8% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #425 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Hoffmann-La Roche Inc. against Screen Holdings Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 65.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.